De interés para:
Innovadores en el sector farmacéutico y MedTech, inversores y profesionales interesados en terapias avanzadas.
Resumen:
Johnson & Johnson Innovation participará en BioEquity, un evento clave en Brujas para el sector farmacéutico y MedTech. Se realizarán dos talleres sobre modelos de inversión en nuevas empresas emergentes y sobre terapias celulares y génicas, abordando desafíos y oportunidades. Además, se invita a participar en una sesión especial el 3 de junio, presencialmente en Utrecht o virtualmente, sobre estrategias de desarrollo de medicamentos.
12 May from 2:00-3:00pm CEST: Alternative Thinking on the NewCo Model: Looking to Pharma for Assets and/or strategies
Much of the news flow about NewCos has focused on Western VCs sourcing assets from Asia. But big pharma is also a source for assets. In this interactive lunch session, the JJDC team will share strategies on how investors can partner with pharma on asset or platform based new company creation.
14 May from 9:00-10:00am CEST: Cell & Gene Therapy: Investment Opportunities and Challenges
Fiona MacLaughlin, JJDC lead for EMEA, will join other leaders to discuss critical issues surrounding ATMPs, from reimbursement and manufacturing challenges, to the potential in solid tumors, and competition from ADCs and other modalities.
Enlace:
Información.
